Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
"In order to avoid possible health risks, the German Federal Office for Radiation Protection recommends that you minimize your personal exposure to radiation through your own initiative." As of 2016, the EMF Guideline 2016 of EUROPAEM (European Academy For Environmental Medicine) on the prevention, diagnosis and treatment of EMF-related complaints and diseases applies.
[19], healthy trees outside of intensively managed environments are unlikely to sustain serious permanent damage from these insects. Both in silvicultural and natural contexts, the beetles themselves remain the most problematic and worrisome components of the symbiosis, and A. roeperi is not in and of itself a severe tree disease, merely a critical foundation for X. crassiusculus nutrition. Disrupting the relationship between fungus and beetle may thus someday provide fruitful avenues for pest control.
It has been indicated that one Mn2+ ion is tightly bound to His370, while the second is loosely bound to Asp276. Human prolidase has four crystal structures, HsProl-Mn, HsProl-Na-GlyPro, HsProl-Mg-LeuPro, and HsProl-Mn-Pro. The first of these structures, HsProl-Mn, pertains to the activity of serum prolidase before binding the substrate. Furthermore, HsProl-Na-GlyPro results from substrate degradation caused by the exchange of the Mn2+ ion with Na+. This is caused by the substrate GlyPro binding to the enzyme. The third crystal structure of serum prolidase is HsProl-Mg-LeuPro. This structure functions similarly to HsProl-Na-GlyPro; however, the substrate utilized in this structure is LeuPro. Additionally, Mn2+ is replaced by Mg2+. These differences cause the structure to be more stable with a lower turnover rate. The final crystal structure of serum prolidase is HsProl-Mn-Pro, which employs Pro as the substrate. This Pro comes from the reaction being catalyzed by this enzyme. The crystal structure of prolidase is well-researched and recorded in the Protein Data Bank.
Benzodiazepines have a unique history in that they were responsible for the largest-ever class-action lawsuit against drug manufacturers in the United Kingdom, involving 14,000 patients and 1,800 law firms that alleged the manufacturers knew of the dependence potential but intentionally withheld this information from doctors. At the same time, 117 general practitioners and 50 health authorities were sued by patients to recover damages for the harmful effects of dependence and withdrawal. This led some doctors to require a signed consent form from their patients and to recommend that all patients be adequately warned of the risks of dependence and withdrawal before starting treatment with benzodiazepines. The court case against the drug manufacturers never reached a verdict; legal aid had been withdrawn and there were allegations that the consultant psychiatrists, the expert witnesses, had a conflict of interest. The court case fell through, at a cost of £30 million, and led to more cautious funding through legal aid for future cases. This made future class action lawsuits less likely to succeed, due to the high cost from financing a smaller number of cases, and increasing charges for losing the case for each person involved. Although antidepressants with anxiolytic properties have been introduced, and there is increasing awareness of the adverse effects of benzodiazepines, prescriptions for short-term anxiety relief have not significantly dropped.
== External links == "MMR (Measles, Mumps, & Rubella) Vaccine Information Statement". U.S. Centers for Disease Control and Prevention (CDC). 22 October 2019. "MMRV (Measles, Mumps, Rubella & Varicella) Vaccine Information Statement". U.S. Centers for Disease Control and Prevention (CDC). 22 October 2019. Measles Vaccine at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
Hence, for the security and prosperity of Chile, the separation of Upper Peru is absolutely convenient, both from the Provinces of the Río de la Plata and from the former Viceroyalty of Lima, and that by forming an independent State it provides us with these two advantages: 1° decrease the preponderance of each of those States, and
For this reason, the elasticity of the ECM or another binding substrate is very important. The tension created by a cell pulling against a stiff substrate needs to reach a certain threshold to allow for mechanotaxis to occur.
== Drinking water hazards == Untreated water may contain potentially pathogenic agents, including protozoa, bacteria, viruses, and some larvae of higher-order parasites such as liver flukes and roundworms. Chemical pollutants such as pesticides, heavy metals and synthetic organics may be present. Other components may affect taste, odour and general aesthetic qualities, including turbidity from soil or clay, colour from humic acid or microscopic algae, odours from certain type of bacteria, particularly Actinomycetes which produce geosmin, and saltiness from brackish or sea water. Common metallic contaminants such as copper and lead can be treated by increasing the pH using soda ash or lime, which precipitates such metals. Careful decanting of the clear water after settlement or the use of filtration provides acceptably low levels of metals. Water contaminated by aluminium or zinc cannot be treated in this way using a strong alkali as higher pHs re-dissolve the metal salts. Salt is difficult to remove except by reverse osmosis or distillation. Most portable treatment processes focus on mitigating human pathogens for safety and removing particulates matter, tastes and odours. Significant pathogens commonly present in the developed world include Giardia, Cryptosporidium, Shigella, hepatitis A virus, Escherichia coli, and enterovirus. In less developed countries there may be risks from cholera and dysentery organisms and a range of tropical enteroparasites.
=== Innovation and novel ideas === Kalra coined the term "barocrinology" to describe the endocrine science of obesity. He has since proposed numerous concepts related to "baro-health" and serves as a section editor in the barocrinology division of a major South Asian PubMed-indexed journal. His contributions include the Barocene Era, barometric nervosa, bariatric pyramid, baromania, baro-bullying, lipokathexis, the Ominous Octet of Obesity, and viewing obesity as a communicable disease—concepts intended to provide simplified frameworks for understanding complex obesity science. He has also developed simple, implementable behavioural therapy models for obesity care. Kalra frequently draws analogies between obesity management and concepts from quantum physics, traditional customs, and religious texts. Several of these ideas have been widely cited and discussed.
Indirect algicidal mechanisms involve no physical contact. Instead, bacteria secrete compounds into the environment that result in the death of algal cells. There is a wide variety of chemical compounds that may have algicidal capabilities, including alkaloids, amino acids, peptides, proteins, carbohydrates, lipids, enzymes, polyketides, terpenoids, and fatty acids. Secretion can be constitutive, in which chemicals are released continuously, or inducible, in which the detection of other molecules or cells trigger their release. There is also evidence that algicidal chemicals act additively. For example, ortho-tyrosine and urocanic acid, both produced by Bacillus sp. B1, had algicidal effects on Heterosigma akashiwo, where ortho-tyrosine affected its photosynthetic system, and urocanic acid damaged its mitochondria.
Sources: en.wikipedia.org
On November 25, Karriem was arraigned on charges of first-degree murder; he pleaded guilty, but his bizarre courtroom behavior convinced witnesses of his insanity. Judge John P. Scallen appointed three psychiatrists. Karriem was described as throwing furniture at other prisoners. Papers described Karriem's confinement in a padded cell of the County Jail, writing "The lustful flame of jungle fanaticism which tortured Harris into murdering Smith, seemed to have died away in him, temporarily at least, Saturday [November 26]." On November 28, "Negro leaders" in Detroit publicly voiced opposition to the "cult". By November 29, police had seized ATI literature including a registry of 8,000 members. On November 30, papers reported that Ugan Ali was likely insane, while Fard was reported as "not driven into his sinister teaching through insanity". On December 1, papers announce that the roster of ATI members had been conveyed to the Welfare Departments; Recipients were to be banned from welfare if they retained their membership. On December 6, the three psychiatrists testified that Karriem was legally insane, and he was committed to the Ionia State Hospital for the Criminal Insane. On December 6, Ugan Ali was released after promising to help disband the Allah Temple of Islam, while Fard agreed to forever leave Detroit as a condition of release. In the state hospital, Karriem was diagnosed with dementia praecox. He died there on June 19, 1935, of "mitral insufficiency and decompensation".
== See also == Drug design Drug metabolism Microbial biodegradation Biodegradation Bioremediation Antioxidant SPORCalc, an example process for exploring xenobiotic and drug metabolism databases Archived 2009-03-18 at the Wayback Machine
In the United States, one of the only countries where CPA has not been approved for medical use, spironolactone is commonly used in transgender women instead. Bicalutamide has certain favorable properties as a potential alternative option to these antiandrogens in transgender females. For example, it is much more potent and selective as an AR antagonist than CPA and spironolactone. However, CPA may be a more potent antiandrogen than bicalutamide in the context of male levels of testosterone, due to its additional action of substantially suppressing testosterone levels at low doses. In transgender women who do not achieve their desired results or are unable to tolerate the side effects of other antiandrogens, switching to bicalutamide may be useful. The World Professional Association for Transgender Health (WPATH) Standards of Care for the Health of Transgender and Gender Diverse People Version 8 (SOC8), released in September 2022, recommends against the routine use of bicalutamide in transfeminine people due to lack of study and data on it in this population and safety concerns such as liver toxicity. Instead, the SOC8 recommends other more established and better-studied antiandrogens, like spironolactone, CPA, and GnRH modulators. Other less prominent transgender health guidelines are mixed in recommending against use of bicalutamide (UCSFTooltip University of California, San Francisco guidelines), cautiously allowing it (Fenway Health guidelines), and recommending it over other antiandrogens (Southern African HIV Clinicians' Society guidelines).
=== Middle Eastern countries === As of March 2026, Nando's has five restaurants in Bahrain; two in Manama and one each in Amwaj Islands, Isa Town and Saar. In Qatar, Nando's has been established since 2001, with the first restaurant located on Salwa Road. As of October 2022, Nando's has eight branches in Qatar, seven of which are located in Doha while one is in Al Wakrah. In Saudi Arabia, Nando's opened its first restaurant within the country on 12 December 2016 in Riyadh, and opened its first branch in Jeddah on 8 December 2018 As of March 2026, Nando's has nine branches in Saudi Arabia; three in Riyadh, three in Jeddah; and one each in Dhahran, Dammam and Khobar. Nando's opened its first restaurant within the United Arab Emirates in Dubai (along Sheikh Zayed Road) in 2002 and opened its first branch in Abu Dhabi in 2014. As of August 2021, Nando's has 19 branches in the UAE; 13 in Dubai, three in Abu Dhabi and one each in Sharjah, Al Ain and Ras Al Khaimah. As a former market, Israel was home to a successful Nando's franchise network throughout the 1990s and 2000s, with the Israeli operation involving the Brozin brothers alongside the international Nando's business. The first Israeli branch opened in Herzliya in 1993, and by 1996 there were branches in Tel Aviv, Herzliya and Haifa, with plans for further expansion. By March 2004, the network had grown to 15 restaurants. In December 2005, Nando's Israel was acquired by Israeli businessman Yuval Doron's Eddy Global Holdings. Kenny Brozin remained chief executive of the Israeli operation until June 2006.
=== Evangelical-Lutheran === Aid Association for Lutherans Concordia Mutual Life Association - Founded in 1908 to sell life insurance to Lutherans. Licensed to sell insurance in 11 states; 1979 membership 25,000. Headquarters in Chicago. Lutheran Brotherhood
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.